Mostrar el registro sencillo del ítem
dc.contributor.author
Nader, Maria Elena Fatima
dc.contributor.author
Vera Pingitore, Esteban
dc.contributor.author
Juárez Tomás, María Silvina
dc.contributor.other
Bitterlich, Ahmed
dc.contributor.other
Fischl, Sahar
dc.date.available
2020-09-08T18:24:35Z
dc.date.issued
2012
dc.identifier.citation
Nader, Maria Elena Fatima; Vera Pingitore, Esteban; Juárez Tomás, María Silvina; Potential applications of bacteriocins as bioactive substances for human health; Nova Science Publishers; 2012; 253-284
dc.identifier.isbn
978-1-61324-865-2
dc.identifier.uri
http://hdl.handle.net/11336/113539
dc.description.abstract
Lactic acid bacteria are constituents of most of the indigenous microbiota or mucosarelated ecosystems, both in humans or animals. During the last years, many bacteriocins produced by bacteria classified into this group were described. Bacteriocins are ribosomally-synthesized antimicrobial peptides produced by a wide range of bacteria. Historically, they were used as bioactive compounds to prevent the growth of pathogen or spoilage microorganisms in foods. The most widely used is nisin, produced by Lactococcus lactis, that is included in the CODEX and has the GRAS (Generally Recognized as Safe) status to be incorporated into different types of processed or longterm storage foods. As bacteriocins are active against many pathogens, potentially pathogens or some drug-resistant pathogens, some of them have been thought as alternative bioactive substances to avoid the broad side-effects and alarming resistance dissemination produced by the use of classical antibiotics. Our research group is working in the design of a beneficial product to prevent prevent women urogenital infections, and we were the first to describe salivaricin CRL 1328, a bacteriocin produced by Lactobacillus salivarius isolated from human vagina. This bioactive compound is heat-stable, and active against a wide variety of urogenital pathogens. The molecular characterization of salivaricin indicates that is constituted by two structural peptides and the evaluation of the mechanism of action reveals that acts by dissipating the proton motive force of the sensitive pathogens. As we are interested to incorporate salivaricin into a pharmaceutical product, the optimization of the culture media and physico-chemical conditions for the higher production were determined. And also the stability to the freeze-drying process and to the long term storage conditions was studied. Some of these experiments were performed by the application of statistical methods that allowed a faster and easier interpretation of the experimental results obtained. The incorporation of bacteriocins as bioactive compounds in a pharmaceutical product needs different type of studies to demonstrate the no existence of adverse effects, which must be performed both in in vitro and in in vivo experimental systems. Most of the bacteriocins do not exert significant cytoxicity or hemolytic activity against human erythrocytes in in vitro assays. Experiments in animal models have shown the success of some lantibiotics for the treatment of infections produced by Streptococcus pneumoniae and methicillin-resistant Staphylococcus aureus (MRSA), and also in the prevention of gingivitis. Nisin is included into a pharmaceutical product to prevent cow mastitis, and is proposed as spermicidal for human use. In this chapter, a revision of many of the bacteriocins described for prevention of human health are reviewed, together with those available commercially, evaluated by in vitro or in vivo assays. Up today, the use of bacteriocins as bioactive compounds into pharmaceutical products for human use has not been accepted yet by the regulators or reference organizations. There are a wide variety of bacteriocins produced by different bacterial genera that must be further studied. More complex experiments are needed to encourage and support the inclusion of these types of bioactive substances into products that could be applied to prevent or treat many of the wide arrays of pathogenic microorganisms that affect human and animal health.
dc.format
application/pdf
dc.language.iso
eng
dc.publisher
Nova Science Publishers
dc.rights
info:eu-repo/semantics/restrictedAccess
dc.rights.uri
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
dc.subject
BACTERIOCIN CLASSIFICATION
dc.subject
BACTERIOCIN CLINICAL APPLICATIONS
dc.subject
BACTERIOCIN PHARMACEUTICAL POTENCIALITIES
dc.subject
SALIVARICIN CRL 1328
dc.subject.classification
Biología Celular, Microbiología
dc.subject.classification
Ciencias Biológicas
dc.subject.classification
CIENCIAS NATURALES Y EXACTAS
dc.title
Potential applications of bacteriocins as bioactive substances for human health
dc.type
info:eu-repo/semantics/publishedVersion
dc.type
info:eu-repo/semantics/bookPart
dc.type
info:ar-repo/semantics/parte de libro
dc.date.updated
2020-08-05T15:21:09Z
dc.journal.pagination
253-284
dc.journal.pais
Estados Unidos
dc.journal.ciudad
New York
dc.description.fil
Fil: Nader, Maria Elena Fatima. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Tucumán. Centro de Referencia para Lactobacilos; Argentina
dc.description.fil
Fil: Vera Pingitore, Esteban. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Tucumán. Centro de Referencia para Lactobacilos; Argentina
dc.description.fil
Fil: Juárez Tomás, María Silvina. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Tucumán. Centro de Referencia para Lactobacilos; Argentina
dc.relation.alternativeid
info:eu-repo/semantics/altIdentifier/url/https://novapublishers.com/shop/bioactive-compounds-types-biological-activities-and-health-effects/
dc.conicet.paginas
438
dc.source.titulo
Bioactive compounds: types, biological activities and health effects
Archivos asociados